Medtech M&A has remained brisk throughout the summer after a busy start to 2026.
In the second quarter, deal volume in the sector was up 36% to 113 transactions, from 83 in the first quarter, marking the busiest period since the first quarter of 2025, according to a recent report from PMCF Investment Banking.
In recent months, Johnson & Johnson sold its Laminar left atrial appendage closure technology for $400 million, and Medtronic took the final steps to split off its MiniMed diabetes tech business.
Several companies announced or closed acquisitions worth more than $1 billion, with Thermo Fisher Scientific completing the $1.1 billion sale of its microbiology unit, Teledyne agreeing to buy Varex Imaging for $1.1 billion, Tempus agreeing to buy cancer blood test maker Personalis for $1.5 billion and investment firm KKR planning to buy device manufacturer Integer Holdings for $5.7 billion. Danaher also closed its $9.9 billion buyout of patient monitoring firm Masimo.
The two largest acquisitions of 2026 made headlines at the start of the year, when Boston Scientific announced plans to buy Penumbra for $14.5 billion and Abbott closed its $21 billion purchase of cancer test firm Exact Sciences.
Several medtech firms have also announced major divestitures in the past year. BD sold its biosciences and diagnostics businesses to Waters and J&J has also shared plans to divest its orthopedics segment.
Here are the top M&A deals so far this year:
